RHEUMATOLOGISTS REPORT WIDESPREAD ADOPTION AND ANTICIPATED GAINS FOR CELGENE’S OTEZLA IN PSORIATIC ARTHRITIS
TNF share expected to erode as Otezla sees greater adoption, according to Spherix Global Insights, GmbH
September 8, 2015 – Zug, Switzerland – Feedback gathered from 101 US rheumatologists during late July and early August reveals a major shift in PsA treatment focused on the uptake and expanded use of Otezla. According to the latest release of RealTime Dynamix: Psoriatic Arthritis, an increasing number of rheumatologists view Otezla as a first line treatment option before the ever-popular TNFs (AbbVie’s Humira, Pfizer/Amgen’s Enbrel, Janssen’s Remicade and Simponi, and UCB’s Cimzia). Comfortable with the safety profile and enamoured with the oral formulation of Otezla, over 40% of current prescribers expect to increase their use in September. Keeping patients on Otezla may be a challenge, however, as the survey revealed a high discontinuation rate due to a variety of factors.
The PsA market will become even more competitive in the near future with pending approvals of Pfizer’s Xeljanz, BMS’ Orencia and Novartis’ Cosentyx – all currently approved for other indications. More than a quarter of surveyed respondents already have off-label experience with these agents in PsA, providing a launch advantage over products like Lilly/Incyte’s Ixekizumab.
It remains to be seen whether Amgen’s reversal on brodalumab due to safety concerns will have any impact on adoption of the IL-17 drug class. Our survey suggests that at least 20% are wary of a class effect, but Valeant Pharmaceutical seems optimistic about the drug, scooping up the marketing rights for brodalumab from AstraZeneca in a deal last week.
About RealTime DynamixTM
RealTime DynamixTM is a monthly service which combines large scale primary market research with unparalleled market understanding to delve into the latest opinions and controversies that are impacting rheumatology, nephrology, neurology and pulmonology markets. The next update of RealTime Dynamix: Psoriatic Arthritis will be available at the end of September.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company with offices in Zug, Switzerland and Cambridge, MA. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
All company, brand or product names in this document may be trademarks of their respective holders.
For more information Contact:
Katharina Skwara, Marketing Manager
Telephone: +41 (0) 41 747 18 76